Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
OBJECTIVE
The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD).


METHODS
In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly assigned to receive 6 weeks of treatment with either atomoxetine (administered once daily) or placebo.


RESULTS
Outcomes among atomoxetine-treated patients were superior to those of the placebo treatment group as assessed by investigator, parent, and teacher ratings. The treatment effect size (0.71) was similar to those observed in previous atomoxetine studies that used twice-daily dosing. Parent diary ratings suggested that drug-specific effects were sustained late in the day. Discontinuations due to adverse events were low (less than 3%) for both treatment groups, and no serious safety concerns were observed.


CONCLUSIONS
Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.
Michelson
David
D
Lilly Research Laboratories, Indianapolis, IN 46285, USA. dmichelson@lilly.com
Allen
Albert J
AJ
Busner
Joan
J
Casat
Charles
C
Dunn
David
D
Kratochvil
Christopher
C
Newcorn
Jeffrey
J
Sallee
F Randy
FR
Sangal
R Bart
RB
Saylor
Keith
K
West
Scott
S
Kelsey
Douglas
D
Wernicke
Joachim
J
Trapp
Nancy J
NJ
Harder
Donald
D
D000293:Adolescent; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D010552:Personality Assessment; D011437:Propylamines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000928:Antidepressive Agents; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride